https://www.selleckchem.com/pr....oducts/trastuzumab-d
Among persons with non-zero expenditure, prefrail and frail persons, on average, had US $30.62 [95% confidence interval (CI) 8.41, 52.82] and US $60.60 (95% CI 5.84, 115.36) higher outpatient expenditure than the nonfrail, adjusting for sociodemographics, multimorbidity, and disability. After adjustment for all covariates, prefrail persons, on average, had US $3.34 (95% CI 0.54, 6.13) higher self-treatment expenditure than the nonfrail. CONCLUSIONS AND IMPLICATIONS Frailty is an independent predictor of higher healthcare
Like
Comment
Share
